UK Markets open in 55 mins

Ocugen, Inc. (OCGN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.8700+0.0900 (+5.06%)
At close: 04:00PM EDT
1.8600 -0.01 (-0.53%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.7800
Open1.8400
Bid0.0000 x 27000
Ask0.0000 x 1300
Day's range1.8100 - 1.8750
52-week range1.6700 - 17.6500
Volume5,133,548
Avg. volume5,286,264
Market cap372.478M
Beta (5Y monthly)4.58
PE ratio (TTM)N/A
EPS (TTM)-0.2530
Earnings date07 Nov 2022 - 11 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.60
  • Motley Fool

    Why Ocugen Stock Topped the Market Today

    Although it hasn't been the most popular coronavirus stock, Ocugen (NASDAQ: OCGN) clearly found some new fans on Thursday. In a one-two punch, Ocugen has appointed a new chief medical officer and chief scientific officer. The former is Robert Hopkins, a physician with over 20 years in both the public and private sectors of the healthcare industry.

  • Motley Fool

    Why Ocugen Stock Is Racing Higher Today

    Shares of clinical-stage biotech Ocugen (NASDAQ: OCGN) are on fire today. Mizuho's analyst noted that Ocugen's shares are only currently being valued at the commercial potential of its COVID-19 vaccine known as Covaxin. Ocugen is co-commercializing the vaccine in North America with its developer Bharat Biotech of India.

  • Motley Fool

    Here's How This Beaten-Down Stock Could 10X by 2024

    On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. To remedy that issue, it's licensing a coronavirus vaccine called Covaxin from Bharat Biotech, an Indian pharmaceutical business. While it's already approved in India, the chances of Ocugen successfully commercializing Covaxin in the U.S. remain a question mark.